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The cellular phenotype is described by a complex network of molecular interactions. Elucidating network
properties that distinguish disease from the healthy cellular state is therefore of critical importance for gain-
ing systems-level insights into disease mechanisms and ultimately for developing improved therapies. By
integrating gene expression data with a protein interaction network to induce a stochastic dynamics on the
network, we here demonstrate that cancer cells are characterised by an increase in the dynamic network
entropy, compared to cells of normal physiology. Using a fundamental relation between the macroscopic re-
silience of a dynamical system and the uncertainty (entropy) in the underlying microscopic processes, we argue
that cancer cells will be more robust to random gene perturbations. In addition, we formally demonstrate that
gene expression differences between normal and cancer tissue are anticorrelated with local dynamic entropy
changes, thus providing a systemic link between gene expression changes at the nodes and their local network
dynamics. In particular, we also find that genes which drive cell-proliferation in cancer cells and which often
encode oncogenes are associated with reductions in the dynamic network entropy. In summary, our results
support the view that the observed increased robustness of cancer cells to perturbation and therapy may be
due to an increase in the dynamic network entropy that allows cells to adapt to the new cellular stresses.
Conversely, genes that exhibit local flux entropy decreases in cancer may render cancer cells more susceptible
to targeted intervention and may therefore represent promising drug targets.
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I. INTRODUCTION
Cancer cells differ from normal cells in terms of a
complex landscape of genomic mutations (more generally
aberrations), which at a systems-level cause a fundamen-
tal dynamic rewiring of the cellular interaction network,
ultimately impairing normal cell physiology and allowing
cells to acquire key cancer hallmarks1. However, the pre-
cise systems-level principles underlying the cancer phe-
notype remain to be elucidated, which represents a key
challenge, not only for achieving a deeper understand-
ing of cancer biology but also for identifying novel drug
targets2.
Ideal drug targets represent genes that upon drug inter-
vention lead to the demise of the cancer cells, while at the
same time not compromising the physiology of the nor-
mal healthy cells. Given that cellular function is deter-
mined by a complex network of protein interactions, one
would wish to intervene at points in the network which
lead to a functional break-down in cancer cells without
affecting their normal cell counterparts. In the parlance
of network theory, one seeks to identify nodes in the can-
cer network which are integral to the robustness of the
cancer network, but which are not so (or less so) for the
a)Electronic mail: a.teschendorff@ucl.ac.uk
normal healthy network. Thus, it is of interest to ex-
plore network properties that may allow us to identify
such nodes.
In this work, we explore the role of dynamic network en-
tropy in cancer. Our motivation to focus on dynamic
network entropy derives from a fluctuation theorem of
dynamical systems theory3 which asserts that the macro-
scopic resilience of a system, R, is correlated to the level
of uncertainty or entropy (disorder), S, of the underlying
microsopic dynamical processes that take place within
that system. More precisely, the theorem states that the
following inequality must hold
∆S∆R > 0 (1)
where ∆R and ∆S represent respectively the changes
to the robustness and entropy of the system3,4. This
inequality holds quite generally, including the case of a
stochastic dynamics defined on an underlying network3,4.
In5,6 this theorem was subsequently applied to protein
interaction networks in yeast and c.elegans, and it was
demonstrated that those genes that contribute most to
the network entropy are more likely to be essential genes
for the organism. However, in these studies, the stochas-
tic matrix defining the dynamics on the network, and
hence the dynamic entropy, was purely topological, i.e
the dynamics and entropy were completely specified by
the underlying network topology.
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In order to explore the role of dynamic network entropy
in cancer, we use static gene expression data from repre-
sentative samples of normal and cancer tissue to approx-
imate a stochastic dynamics on a human protein interac-
tion network. Thus, the dynamics refers to the random
walk generated by a stochastic matrix on the network,
and not to an underlying temporal dynamics, as time
course data for individual cancer patients is not avail-
able. As we shall see, the dynamics on the network is
not entirely specified by the network topology. In fact,
we assume that the network topology is unchanged be-
tween the normal and cancer phenotypes, but allow the
dynamics, defining the weights in the network, to be de-
pendent on the phenotype. Equivalently, we view the
protein interaction network as providing only a backbone
topological structure as to which interactions are allowed,
and use the phenotype-specific gene expression data (and
specifically, the correlations in gene expression over the
disease phenotype) to modulate and approximate the in-
teraction probabilities. Using this perspective, cancer
cells differ from normal cells due to a differential dynam-
ics on the same underlying network.
Therefore, our approach is based on two key concepts.
First, the integration of gene expression data with pro-
tein interaction networks to yield integrated weighted
networks, a methodological approach which has already
proved fruitful in a variety of different applications
within the cancer genomics field7–21. Secondly, we use
the recent notion of “differential networks”, which at-
tempts to better characterise disease phenotypes by
studying the changes in the interaction patterns of these
networks2,13,14,19,22,23, as opposed to merely analysing
the changes in mean levels of some molecular quan-
tity (e.g gene expression). As demonstrated by several
studies13,14,19, differential networks can identify impor-
tant gene modules implicated in cancer and also pro-
vide critical novel biological insights not obtainable using
other approaches. This differential network strategy has
recently received further impetus from studies of differ-
ential epistasis mapping in yeast, demonstrating that dif-
ferential interactions may hold the key to understanding
the systems-level responses of cells to exogenous and en-
dogenous perturbations, including those present in can-
cer cells2,22.
This work is organized as follows. We begin by re-
viewing the notion of local dynamic network entropy,
as constructed from an integrated gene expression pro-
tein interaction network, and which was introduced by
us previously19. We next extend this notion of local dy-
namic entropy to a non-local/global one, i.e for extended
subnetworks. We then explore the local and non-local
dynamic entropy changes associated with the cancer cell
phenotype. We point out that previously we had only
compared local entropy measures between metastatic and
non-metastatic breast cancer19, but not between cancer
and normal tissue, as data sets containing larger normal
sample collection were less readily available. We also ex-
plore the relation between local differential entropy and
differential expression. Finally, using the above entropy-
robustness theorem, we discuss the potential implica-
tions of our findings for devising novel cancer therapies
with a view to future studies that will attempt to inte-
grate drug sensitivity data with multi-dimensional (mu-
tational, copy-number, epigenetic and transcriptomic)
tumour profiles.
II. METHODS
The protein interaction network (PIN)
We downloaded the complete human pro-
tein interaction network from Pathway Commons
(www.pathwaycommons.org) (Jan.2011)24, which brings
together protein interactions from several distinct
sources. We then built a reduced protein interac-
tion network from integrating the following sources:
the Human Protein Reference Database (HPRD)25,
the National Cancer Institute Nature Pathway In-
teraction Database (NCI-PID) (pid.nci.nih.gov), the
Interactome (Intact) http://www.ebi.ac.uk/intact/
and the Molecular Interaction Database (MINT)
http://mint.bio.uniroma2.it/mint/. Protein interactions
in this network include physical stable interactions such
as those defining protein complexes, as well as transient
interactions such as post-translational modifications and
enzymatic reactions found in signal transduction path-
ways, including 20 highly curated immune and cancer
signaling pathways from NetPath (www.netpath.org)26 .
We focused on non-redundant interactions, only included
nodes with an Entrez gene ID annotation and focused
on the maximally conntected component, resulting in a
connected network of 10,720 nodes (unique Entrez IDs)
and 152,889 documented interactions. In what follows
we refer to this network as the “PIN”.
Normal and cancer tissue gene expression data sets
We searched Oncomine27 for studies which (i) had pro-
filed reasonable numbers of cancer and normal tissue
samples (at least ∼ 25 of each type), and (ii) which had
been profiled on an Affymetrix platform. In order to reli-
ably estimate covariance of two genes across a set of sam-
ples, at least ∼ 25 samples are needed. The second crite-
rion reflects the desire to conduct the study on a common
platform and Affymetrix arrays are the most widely used.
Using the same platform across studies ensured that the
integrated mRNA-PIN networks were of similar size. In
all cases, the intra-array normalised data was downloaded
from GEO (www.ncbi.nlm.nih.gov/geo/), quantile nor-
malized, and subsequently probes mapping to the same
Entrez gene ID were averaged. We then subjected each
study that passed these criteria through a quality con-
trol step, which involved a Principal Component Analy-
sis (PCA) to check that (iii) the dominant component of
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variation correlated with cancer/normal status. If not,
this indicated to us a more pronounced source of non-
biological variation, which would confound our down-
stream analysis. There were six studies satisfying all
three criteria and the tissues profiled included bladder
(48 normals and 81 cancers)28, lung (49 normals and 58
cancers)29, gastric (31 normals and 38 cancers)30, pan-
creas (39 normals and cancers)31, cervix (24 normals and
33 cancers32 and liver (23 normals and 35 cancers)33.
Integrated PIN-mRNA expression networks and the
stochastic information flux matrix
For a given cellular phenotype (i.e. cancer or normal),
we build an integrated mRNA-PIN using the same pro-
cedure as described in19. Briefly, edge weights in the PIN
are defined by a stochastic matrix pij ,
pij =
wij∑
k∈N (i) wik
(2)
with
∑
j∈N (i) pij = 1, where N (i) denotes the neigh-
bors of gene i in the PIN and where wij =
1
2 (1 + Cij)
denotes the transformed Pearson correlation coefficient
Cij of gene expression between genes i and j across the
samples belonging to the given phenotype. This defini-
tion of wij reflects our desire to treat correlations and
anti-correlations differently. We also note that we en-
force pij = 0 whenever (i, j) is not an edge in the PIN.
Thus, the integrated mRNA-PINs with the edge weights
as defined by pij , can be viewed as approximate models
of signal transduction flow (as measured by positive gene-
gene correlations in expression) subject to the structural
constraint of the PIN. Applying this procedure to the two
phenotypes yields two integrated PIN-mRNA networks,
one for the cancer phenotype with stochastic matrix p
(C)
ij ,
and one for the normal phenotype with stochastic matrix
p
(N)
ij . It is important to point out that the construction of
our stochastic matrix means that the topological degrees
of each node remain unchanged between the normal and
cancer phenotypes: it is only the weights specifying the
random walk on the network which differ between the
two phenotypes.
It is important to stress that we have approximated signal
transduction flux on the PIN by positive correlations in
expression between interacting genes. This is obviously
a crude approximation and therefore a limitation of this
study, however, until other types of matched molecular
data (e.g protein expression, phosphorylation and other
post-translational modification states) become available
on a genome-wide basis, we are restricted to the use of
only gene expression data. Some further justification for
the use of gene expression correlations to approximate
signaling flux over the network will be provided by care-
ful comparison of the local correlations to those which
are non-local.
A heat kernel stochastic matrix
It is clear that the stochastic matrix pij above defines a
(biased) random walk on the network N . One may thus
compute an information (or probability) flux between any
two nodes i and j in N 34. In fact, it is clear that the
probability flux of moving from i to j over a path of
length L is given by (pL)ij . It follows that the total
probability flux Eij between i and j is given by
Eij = γ
∞∑
L=1
αL(p
L)ij (3)
where γ is a normalisation factor and where we have in-
troduced a set of arbitrary weights αL to allow variable
contributions for paths of different lengths. One possibil-
ity is to suppress paths of longer lengths using αL = 1/L!,
which also guarantees convergence of the infinite series34.
Formally, defining αL = t
L/L!, we obtain the stochastic
matrix
Kij(t) =
∑∞
L=1
tL
L! (p
L)ij
et − 1
(4)
where we have introduced a “temperature” parameter
t35. This stochastic matrix is a modified version of the
heat-kernel stochastic matrix35 and satisfies
∂tK(t) = −K(t)(I − p) +
p−K(t)
et − 1
(5)
where we have suppressed matrix indices and where I de-
notes the identity matrix. Since pij ,Kij(t) ≤ 1 ∀i, j, t,
it follows that for sufficiently large temperatures (t ≥
1), K(t) approximates a solution of the heat-diffusion
equation35
∂tK(t) ≈ −K(t)(I − p) (6)
Thus, the choice α = tL/L! leads to a natural interpreta-
tion in terms of a discrete approximate diffusion process
on a graph36. This construction is therefore closely re-
lated to the heat kernel PageRank algorithm35–37.
The dynamic network entropy
Given the matrix Kij , let Q denote the number of non-
zero Kij , i.e Q =
∑
ij I(Kij > 0) where I is here the
indicator function. We then define a dynamic (or flux)
entropy as
SN (t) = −
1
logQ
∑
ij
Kij(t) logKij(t) (7)
where we have rescaled Kij(t) by 1/n in order to en-
sure that
∑
ij Kij(t) = 1. Note that the entropy defined
above can be thought of as a non-equilibrium entropy,
since the stationary distribution pii of Kij , defined by
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piiKij = pij , was not included. Our choice to consider
this non-equilibrium version is motivated by our desire
to avoid biasing the entropic contribution of each node
to its topological properties (e.g degree).
Suppose now that we consider diffusion/flux over paths
of maximum length 1. Then, this leads to Kij = pij/n
where n is the number of nodes in N (we have set t = 1
for convenience). This leads to the expression
S
(1)
N
=
1
logQ
{−
1
n
∑
ij
pij log pij + logn}
=
1
logQ
{
1
n
∑
i
Si log ki + logn}
In the above expression, Si is the local dynamic entropy
of node i19,36,
Si = −
1
log ki
∑
j∈N (i)
pij log pij (8)
where ki is the degree of node i and the normalisation
factor ensures that the maximum attainable entropy is
equal to 1, independent of the degree of the node.
Next, we can consider flux over paths up to length two,
in which case
K
(2)
ij =
pij +
1
2 (p
2)ij
3
2n
(9)
and the corresponding entropy,
S
(2)
N
= −
1
logQ
∑
ij
K
(2)
ij logK
(2)
ij (10)
In principle, we can estimate the dynamic entropy S(h)
for paths of arbitrary order h. In this case,
K
(h)
ij =
1
n
∑h
r=1
1
r!
(
h∑
r=1
1
r!
(pr)ij
)
(11)
In this work we compute dynamic entropies up to mo-
ments of order 5 using the R-package expm. Not going
beyond h = 5 is justified for two reasons: (i) the most
interesting behaviour is found for h ≤ 3, (ii) the com-
putational cost for h = 5 is considerable, for instance,
estimation of flux entropy and associated sampling vari-
ance estimates for a typical data set of 30 samples and
∼ 7500 nodes at h = 5 takes at least ∼ 20 hours on a
high-performance quad processor workstation.
Sampling variance using the jackknife
To estimate the statistical significance of observed dif-
ferences in entropy between two phenotypes, we decided
to use the jackknife procedure38. Briefly, the jackknife
procedure removes one sample at a time from the given
phenotype and recomputes the desired quantity S (here
entropy). Thus, if there are n samples in the given phe-
notype one obtains n jackknife estimates (SˆJ,j : j =
1, ..., n). A jackknife estimate for the mean Sµ and vari-
ance SV of S is then obtained as
Sˆµ = nSˆ − (n− 1)〈SˆJ,j〉j
SˆV =
n− 1
n
n∑
j=1
(SˆJ,j − 〈SˆJ,j〉j)
where Sˆ is the estimate using all n samples and 〈SˆJ,j〉j =
1
n
∑n
j=1 SˆJ,j . Thus, for two phenotypes “N” and “C”, we
compute the difference ∆SJ = Sˆ
(C)
µ − Sˆ
(N)
µ and obtain a
z-statistic
z =
∆SJ
σJ
(12)
where σJ =
√
S
(N)
V + S
(C)
V .
This jackknife procedure can be applied to the dynamic
entropy defined over the network or for each node individ-
ually. Note that in the case where we obtain z-statistics
for each gene/node, the genes can then be ranked ac-
cording to the significance of this z-statistic. We also
note that by construction the z-statistic should be in-
dependent of the degree of the node. In fact, while
both the differential entropy ∆SJ as well as the stan-
dard deviation estimate σJ will demonstrate the same
degree-dependence, the ratio given by the z-statistic
z = ∆SJ(k)/σJ (k) should be degree independent. We
demonstrate this empirically across the six different data
sets considered here.
It should be pointed out that although bootstrapping
provides an alternative to the jackknife, that it is not
appropriate here since the resampling with replacement
would artifically inflate correlations. Another procedure
could be to permute the phenotype labels, so that a given
“permuted” phenotype contains now a mixture of “nor-
mals” and “cancers”. However, because there are big dif-
ferences in expression between normal and cancer, this
procedure would dramatically alter the distribution of
correlations within the new permuted phenotypes which
would also not yield the correct null distribution. Thus,
the jackknife strategy circumvents this difficulty while
also avoiding the bias associated with bootstrapping.
III. RESULTS
We identified six expression data sets encompassing
sufficient numbers of normal and cancer tissue samples
and which passed our quality control criteria (Methods).
The tissues profiled were bladder, lung, stomach, pan-
creas, cervix and liver. Integration of these expression
data sets with our protein interaction network (PIN)
(Methods) yielded sparse weighted networks of approxi-
mately 7500 nodes and 98500 edges. The average degree,
median degree and diameter of these integrated networks
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FIG. 1. Boxplots of local (i.e. per node) dynamic network entropies (y-axis, DynS) in cancer (C) and normal (N) tissue
for all nodes with degree ≥ 10 (∼ 3500 nodes) and across the six different tissue types. P-values are from a one-tailed
unpaired Wilcoxon rank sum test. Dynamic entropies have been normalised so that the maximum attainable value is 1. See
Supplementary Figure Fig.S2 for the corresponding plot using all nodes with degree ≥ 2
were approximately 26, 8 and 12, respectively. An im-
portant assumption underlying any analysis on these in-
tegrated networks is that genes which are neighbors in
the network are more likely to be correlated at the level
of gene expression. While this has been shown for spe-
cific data sets (see e.g13), we verified that it also holds
for the integrated mRNA-PIN networks considered here
(Fig.S1).
Increased local dynamic entropy is a key hallmark of the
cancer cell phenotype
We previously showed that primary breast cancers that
metastasize exhibit an increased dynamic entropy com-
pared to breast cancers that do not spread19. Compar-
ing distinct cancer phenotypes (e.g metastasizing cancers
to non-metastasizing) to each other has the advantage
that large sample collections are available, thus allow-
ing for more reliable estimates of expression correlations.
However, having identified suitable expression data sets
encompassing relatively large and balanced numbers of
normal and cancer samples, we here sought to determine
if the dynamic network entropy also discriminates can-
cer from its respective normal tissue phenotype. We first
compared the local dynamic entropies between normal
and cancer, focusing on high-degree nodes (here, nodes
with at least 10 neighbours) following the assumption
that high degree nodes have higher relevance in cancer13.
Performing this comparison across six different tissue
types, using both unpaired and paired non-parametric
statistics, clearly confirmed that cancer is indeed charac-
terised by an increased dynamic network entropy (Fig.1,
Table I). Next, we sought to determine if this increased
dynamic entropy is also seen if all nodes are included in
the analysis. The analogous analysis over all nodes of
degree ≥ 2 (to define the local entropy we need a node
to have at least two neighbours) confirmed that dynamic
network entropy is increased in cancer (Fig.S2), with the
TABLE I. Wilcoxon rank sum test statistics comparing the
local dynamic entropies (DynS) between normal and cancer,
and across the six tissue types. We provide statistics and P-
values for the paired (i.e treating the cancer and normal en-
tropies for each gene as dependent variables) Wilcoxon rank
sum test. The test-statistics have been normalised to lie be-
tween 0 and 1, and thus correspond to an AUC (Area Under
receiver operating Curve). AUC values close to 0.5 mean
no discrimination, while AUC values closer to 1 indicate a
highly significant discrimination between normal and cancer.
The corresponding P-values assess the significance of the de-
viation from 0.5 under a one-tailed test, so that it specifically
measures significance of higher entropy in cancer. The top
two rows represent the statistics when considering nodes of
degree ≥ 10, while the bottom rows correspond to all nodes
for which the entropy can be defined, i.e nodes of degree ≥ 2.
BLAD. LUNG GAST. PANC. CERV. LIV.
k ≥ 10
AUC 0.75 0.92 0.69 0.97 0.88 0.88
P < 10−50 < 10−50 < 10−50 < 10−50 < 10−50 < 10−50
k ≥ 2
AUC 0.76 0.84 0.69 0.89 0.78 0.77
P < 10−50 < 10−50 < 10−50 < 10−50 < 10−50 < 10−50
discriminatory power somewhat reduced but still highly
significant (Table I).
We observed that the magnitude of differential en-
tropy change was strongly anti-correlated to node de-
gree (Fig.2A). This dependence of dynamic entropy and
differential dynamic entropy on the degree of the node
was already explored by us previously and reflects an
intrinsic bias which needs to be corrected for if mean-
ingful rankings of genes are to be obtained19. In or-
der to correct for this bias, we here devised a statistical
framework based on the jackknife to derive z-statistics
of differential entropy, which, by construction, would be
degree-independent (Methods). Confirming this, we ob-
served that absolute z-statistics did not exhibit a strong
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anti-correlation with degree, and in fact were on the
whole degree-independent (Fig.2B). Supporting our pre-
vious result, we also observed that differential entropy
z-statistics were significantly higher in cancer compared
to normal tissue, independently of tissue type (Fig.S3).
Non-local dynamic entropy is increased in cancer, albeit
weaker than local dynamic entropy
Next, we asked if the higher order dynamic entropy,
computed over paths of length larger than 1, are also
discriminatory. To this end, we computed for the normal
and cancer phenotypes, a higher-order dynamic network
entropy
S
(2)
N ∝ −
∑
ij
K
(2)
ij logK
(2)
ij (13)
where K
(2)
ij satisfies an approximate diffusion equation
over the network allowing for paths of maximum length
2 (Methods). We point out that even when i and j are
neighbors, that K
(2)
ij is not equal to pij , since we allow
for alternative signaling paths (of maximum length 2)
between genes i and j. Thus, this dynamic entropy also
takes the well-known redundancy of signaling paths into
account39. For S(2), we also observed a higher dynamic
entropy in cancer compared to normal tissue across all
tissue types, although this increase was statistically sig-
nificant only for the four larger studies (Fig.3). We also
computed higher order entropies up to paths of maximum
length 5. However, as with S(2), higher order dynamic
entropies S(k), k ≥ 3 generally exhibited reduced discrim-
inatory power, suggesting that the interesting changes
associated with dynamic entropy in cancer are localised
to neighbors and nearest neighbors in the interaction net-
work.
Differential dynamic entropy and differential expression are
anti-correlated
We argued that if the observed changes in dynamic
entropy have a biological basis, that there should be a
relationship between the changes in local entropy and
gene expression. Specifically, genes which become inac-
tivated in cancer generally exhibit lower expression and
this should be reflected as an increased local dynamic
entropy around these nodes. Conversely, we hypothe-
sized that genes which become activated in cancer (i.e
oncogenes), and which are thus more likely to exhibit
higher expression in cancer, would be associated with
a lower dynamic entropy since the increased activity
of oncogenes is normally associated with activation
of specific downstream signal transduction pathways.
This means that there is less uncertainty (i.e entropy)
along which paths in the network the information flow
proceeds. To test this hypothesis, we computed for each
TABLE II. We provide the Pearson Correlation Coefficient
(PCC) and P-value (P) between the differential entropy z-
statistics z(dS), and the node degree k (top two rows), be-
tween the differential entropy z-statistics and the t-statistic
of differential expression t(dE) (middle two rows) and finally
also the Partial Correlation Coefficient and P-value between
z(dS) and t(dE) after adjustment for k (bottom two rows).
BLAD. LUNG GAST. PANC. CERV. LIV.
z(dS) ∼ k
PCC 0.02 0.08 0.15 0.07 0.09 0.03
P 0.76 0.06 0.09 0.02 0.22 0.72
z(dS) ∼ t(dE)
PCC -0.48 -0.12 -0.21 -0.14 -0.23 -0.29
P 8e-13 0.005 0.02 1e-6 0.001 6e-5
z(dS) ∼ t(dE)|k
PCC -0.49 -0.14 -0.23 -0.15 -0.23 -0.29
P 6e-15 0.001 0.009 3e-7 7e-4 3e-5
TABLE III. Relation between differential expression and dif-
ferential dynamical entropy (DynS). The odds ratio (OR) re-
flects the odds of a gene overexpressed in cancer showing re-
duced dynamical entropy in cancer, compared to a gene that
is underexpressed. The P-value (P) reflects the statistical sig-
nificance of the odds ratio.
BLAD. LUNG GAST. PANC. CERV. LIV.
OR 6.24 3.07 2.43 2.17 3.64 2.80
P 3e-9 0.04 0.05 0.03 0.02 0.005
gene a regularized t-statistic40 that reflects the degree of
differential expression between normal and cancer tissue.
Similarly, for each gene we used the previous jackknife
procedure to obtain a z-statistic which is a statistical
measure of the differential entropy change between the
normal and cancer phenotype (Methods).
Next, we selected those genes with significant changes
in both differential expression and differential dynamic
entropy (P < 0.05). Restricting to these genes, we first
verified that differential entropy statistics were not corre-
lated with degree (Table II). In contrast, differential en-
tropy statistics exhibited a strong anti-correlation with
differential expression independently of tissue type, and
these anti-correlations remained significant after adjust-
ment for node degree (Table II). Confirming this analy-
sis further, we observed that genes significantly overex-
pressed in cancer showed preferential reductions in dy-
namic entropy compared to genes which were underex-
pressed, and the associated odds ratios (OR) were statis-
tically significant across all 6 tissue types (Table III).
Cell-cycle/proliferation genes preferentially associate with a
lower dynamic entropy in cancer
Overexpression of cell-cycle and cell-proliferation
genes is a key cancer hallmark with many of these genes
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FIG. 2. A)Scatterplots of absolute differential dynamic entropy changes between normal and cancer (y-axis) against log2(k)
(x-axis) where k is the degree of the node, for each tissue type. B)Scatterplots of the corresponding absolute differential entropy
z-statistics (y-axis) against log2(k) (x-axis). In both cases, we provide the Spearman rank correlation coefficient.
FIG. 3. z-statistics of differential non-local dynamic entropy
(x-axis) for the six different tissues (y-axis). The dynamic
entropy considered here is the S(2) measure which is defined
for a stochastic diffusion matrix for maximum path lengths of
order 2 (Methods). Positive z-statistics means higher entropy
in cancer compared to normal. Green lines indicate the 95%
confidence interval envelope and given P-values are from a
normal null distribution centred at zero.
representing also candidate drug targets1. Although we
have seen that differential entropy changes anti-correlate
with differential expression, it is important to check
if (1) cell-cycle/proliferation genes are preferentially
associated with a reduced dynamic entropy, and (2)
whether the anti-correlation between differential entropy
and differential expression is driven entirely by cell-cycle
genes. To address the first point, we performed a gene
set enrichment analysis (GSEA) using the Molecular Sig-
TABLE IV. Enrichment analysis of cell-cycle genes among
the top 10% ranked genes exhibiting entropy increases (C>N)
and decreases (N>C) in cancer (C) compared to normal (N)
tissue . The enrichment odds ratio (OR) and P-value (P) is
from a one-tailed Fisher’s exact test. NA=not available due
to insufficient number of genes among the top 10%.
BLAD. LUNG GAST. PANC. CERV. LIV.
DynS(N>C)
OR 3.92 6.07 1.35 NA 2.62 6.61
P 2e-8 0.07 0.17 NA 0.04 4e-11
DynS(C>N)
OR 0.44 0.72 1.13 0.50 1.04 0.50
P 0.99 0.93 0.36 0.99 0.46 0.99
natures Database (MSigDB,41) on the top ranked genes,
ranked according to the statistics of differential dynamic
entropy (separately for increased and reduced entropy).
The GSEA analysis showed that genes implicated in the
cell-cycle were indeed strongly enriched among genes
exhibiting lower dynamic entropy in cancer, but not so
among genes exhibiting increases in dynamic entropy
(Table IV).
To address the second point, we repeated the correla-
tion analysis between differential entropy and differen-
tial expression, but removing cell-cycle genes prior to
the analysis. Importantly, we still observed the anti-
correlation between differential entropy and differential
expression in 5 of the 6 tissue types (Table S1), indicat-
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ing that this anticorrelation is a general systemic feature.
It could be argued that since tumour expression profiles
analyzed here are from the bulk, meaning that the mea-
sured expression profiles represent an average over ep-
ithelial tumour cells and non-epithelial stromal cells (e.g
immune cells), that entropy changes are entirely con-
founded by changes in the tumour-stromal cell composi-
tion. Therefore, it is important to point out here that
the enrichment of cell-cycle/proliferation genes among
those showing the largest reductions in dynamic entropy,
indicates that these differential entropy changes reflect
underlying changes in the epithelial tumour cell popula-
tion, and not changes in the tumour-stromal cell ratio.
In other words, the fact that entropy changes can retrieve
known tumour cell biology (i.e increased proliferation of
tumour cells) shows that interesting tumour cell biology
can be extracted from the dynamic entropy.
DISCUSSION
In this work we have constructed a dynamic network
entropy and have shown that it is increased in cancer
compared to normal tissue. Both local and non-local ver-
sions of the dynamic entropy were considered, with the
local entropy exhibiting the more significant increases.
This partly reflects the local nature of expression corre-
lations in the protein interaction network with correla-
tions dropping significantly beyond neighbours and sec-
ond nearest neighbours (Fig.S4).
While dynamic entropy provided a good discrimination
between normal and cancer tissue, it is clear that it does
not outperform raw gene expression levels, which offer
significantly higher classification accuracies27. Neverthe-
less, the fact that dynamic entropy is significantly dif-
ferent between cancer and normal tissue is an important
observation, specially in light of the entropy-robustness
theorem (Eq.1). Other network measures may also pro-
vide equally good discriminators of the cancer phenotype
than dynamic entropy. Indeed, the average of the abso-
lute correlations over neighbours of a given node provides
an equally good discriminator (Fig.S5), indicating that
the loss of local connectivity is a key cancer characteris-
tic. However, the loss of local connectivity (i.e reduced
absolute correlations) does correspond to an increase in
local dynamic entropy. Therefore, dynamic entropy pro-
vides, through inequality ∆S∆R > 0, a more meaningful
framework in which to interpret and understand the sys-
temic changes in gene expression between normal and
cancer tissue.
It is of importance to discuss (i) what may cause cancer
cells to exhibit the observed increase in dynamic entropy
and (ii) what it may mean for the cancer phenotype itself.
Concerning the first question, one would expect genes
that become inactivated in cancer to represent foci of in-
creased dynamic entropy since the inactivation compro-
mises its biological function: at the level of mRNA ex-
pression this would manifest itself as reduced expression
correlations with its interacting neighbors, but more gen-
erally as an increased uncertainty as to which neighbors
it may interact with. Conversely, for a gene that is over-
activated in cancer its biological function is enhanced,
thus confering the cell a selective advantage, which for
oncogenes manifests itself as an increased flux of the asso-
ciated oncogenic pathway. In terms of the local dynamic
entropy this increased flux along a particular pathway
in the network corresponds to a reduced uncertainty (i.e
less dynamic entropy) along which path the information
is transferred. In line with these biological expectations
we did observe that genes overexpressed in cancer were
significantly more likely to exhibit reductions in dynamic
entropy than underexpressed genes. Thus, the fact that
cancers were characterised globally by an increased dy-
namic entropy points towards a higher frequency of inac-
tivating over activating alterations in cancer. Intuitively,
this makes sense since a random mutation/alteration is
more likely to inactivate than activate a gene, and indeed
this would be in agreement with recent reports suggesting
that most genetic alterations are inactivating and affect
tumour suppressors42. We should point out that to for-
mally demonstrate that the increased dynamic entropy
is associated with an increased frequency of inactivat-
ing alterations (mutations, losses and deletions, promoter
DNA methylation) in the tumours analysed here is not
possible as matched mutational, copy-number and DNA
methylation information is not available for these spe-
cific tumours. However, it will be interesting to explore
this in the context of the matched multi-dimensional can-
cer genomic data from the The Cancer Genome Atlas
(TCGA)43.
Concerning the second question posed above, we pro-
pose that the increased dynamic entropy in cancer could
underpin the intrinsic robustness of cancer cells to en-
dogenous and exogeneous perturbations, including ther-
apeutic intervention. This follows directly from the
robustness-entropy theorem, ∆S∆R > 0. However, as
we have seen, not all genes exhibit increases in dynamic
entropy, with many also exhibiting significant reductions
of dynamic entropy in cancer. In particular, we have seen
that genes driving cell-proliferation, which are known to
be overexpressed in cancer27, were preferentially associ-
ated with significant reductions in the dynamic entropy.
It follows from the above inequality that cancer alter-
ations that are associated with such entropy reductions
will make these cells less dynamically robust. Interest-
ingly, this would fit in well with one of the important
cancer hallmarks, namely, that of oncogene addiction,
whereby cancer cells become overly reliant on a specific
oncogenic pathway1. Indeed, in cases where the oncogene
is druggable, targeting of the oncogene has proved to be
an effective drug therapy strategy1. Thus, our finding
that cell-cycle and cell proliferation genes, which often
encode oncogenes, were preferentially associated with re-
ductions in dynamic entropy (and hence reductions in
robustness) is consistent with known cancer biology.
It follows that the dynamic entropy may be used to iden-
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tify novel drug targets. As a specific example, we ob-
served that the kinase AURKB exhibited the largest re-
ductions in dynamic entropy in bladder cancer (Table
S2). Importantly, AURKA, which has already a well
established oncogenic role in bladder cancer (see e.g44)
was also highly ranked (Table S2). Thus, our analysis
suggests that the closely related kinase, AURKB, which
has already been implicated as an oncogene and poten-
tial drug target in other cancers45–47, may also play an
equally important role in the pathogenesis of bladder can-
cer. Given that AURKB is also druggable (by the drug
rebamipide)48, this kinase therefore represents an attrac-
tive drug target for those bladder cancers that overex-
press it. In cases where the oncogene is not directly
druggable, we speculate that differential dynamic entropy
may be used to identify neighboring druggable targets
that also exhibit significant reductions in dynamic en-
tropy. This novel computational strategy could therefore
guide non-oncogene addiction based therapeutic strate-
gies that aim to select drug targets within the same onco-
genic pathway49,50. Moreover, it has become clear that
mutational and copy-number status alone or in combi-
nation with gene expression levels are not highly predic-
tive of drug response51,52, hence there is an urgent need
for improved in-silico predictors of drug sensitivity. We
leave these open and exciting questions for a future bioin-
formatic study that will analyze matched genomic (mu-
tational, copy-number), epigenomic (DNA methylation),
functional (e.g mRNA expression) and drug sensitivity
data for large panels of drugs and cancer cell-lines51,52.
CONCLUSIONS
In summary, in this work we have explored the notion
of dynamic network entropy in cancer and have shown
that increased dynamic entropy is a key cancer hall-
mark. Given the correlation between dynamic network
entropy and the system’s robustness, further investiga-
tion of the statistical mechanical principles characteris-
ing cancer gene networks is warranted as this may help
rationalize the choice of drug targets.
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